A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

HPV Clinical Trial

Official title:

Phase II Trial Evaluating Selective Minimal Residual Disease Directed Adjuvant Radiation in Human Papilloma Virus Associated Oropharynx Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05307939
• Other study ID #: 21-434
• Status: Recruiting
• Phase: Phase 2
• Start date: March 24, 2022
• Est. completion date: March 24, 2025

Study information

• Verified date: January 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: Linda Chen, MD
• Phone: 201-775-7447
• Email: chenl1[@]mskcc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have this surgery. In Arm A the researchers will see whether monitoring participants' HPV ctDNA levels can safely identify patients who do not need radiation therapy (RT) after surgery and whose RT can be delayed until their HPV ctDNA levels become detectable. In Arm B, the researchers will see whether patients who usually need 6-6.5 weeks of CRT can be selected by HPV ctDNA to receive 3 weeks of CRT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: March 24, 2025
• Est. primary completion date: March 24, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18
• ECOG 0-2
• HPV-16 squamous cell carcinoma of the oropharynx or HPV-16 head and neck squamous cell carcinoma of unknown primary . HPV status must be confirmed by in-situ hybridization.
• HPV ctDNA detectable by HPV digital PCR (Naveris assay) with a minimum of 50 copies/mL pre-operatively.
• Surgical resection of all gross disease with no gross disease visualized on post-operative imaging. o For patients with pT0 (unknown primary) evaluation for the primary should include PET/CT, direct laryngoscopy, ipsilateral tonsillectomy, and targeted biopsy. This should be followed by a neck dissection.
• Two, undetectable (<1 copy/mL) post-operative HPV ctDNA within 2-6 weeks following surgery (blood drawn at least one week apart preferred).
• A minimum of one of the following pathologic criteria: (Arm A)
• AJCC 7 Stage: pT0N1-N2b, pT1N1, pT2N1, or =pT3
• AJCC 7 =pN2
• Lymphovascular invasion
• Perineural invasion
• Close pathologic margin (= 3 mm)
• Signed informed consent form by the participant or their legally authorized representative (LAR).
• A minimum of one of the following pathologic criteria (Arm B):
• Microscopic positive margin
• Extracapsular extension
• Signed informed consent form by the participant or their legally authorized representative (LAR).

Additional criteria for Arm B only:

• Adequate hematologic function within 30 days prior to registration, defined as

follows:

• White Blood Count (WBC) = 2 K/mcL
• Absolute neutrophil count (ANC) = 1,000 cells/mm3
• Platelets = 100,000 cells/mm3
• Hemoglobin = 8.0 g/dl; Note: The use of transfusion or other intervention to achieve Hgb = 8.0 g/dl is acceptable
• Adequate renal function within 30 days prior to registration, defined as follows:
• Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) = 50 ml/min determined

by 24-hour collection or estimated by Cockcroft-Gault formula:

• CCr male = [(140 - age) x (wt in kg)] divided by [(Serum Cr mg/dl) x (72)]
• CCr female = 0.85 x (CrCl male)
• Adequate hepatic function within 30 days prior to registration, defined as follows:
• Bilirubin < 2 mg/dl o AST or ALT < 3 x the upper limit of normal
• Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential

Exclusion Criteria:

• Metastatic disease
• Non-HPV16 genotype (i.e. HPV-18,-31, -33, -35)
• Patients who receive surgery at outside institution. Exceptions can be made for high-volume surgical centers at the discretion of the PI/co-PI
• Prior head and neck radiation
• Patients without pre-operative HPV ctDNA or pre-operative HPV ctDNA = 50 copies/mL
• Subjects with simultaneous primary cancers outside of the oropharynx o Note: Exceptions can be made for patients with simultaneous primaries outside of the oropharynx if determined by the PI/Co-PI, then the patient can proceed with protocol activities
• Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years is 90% or greater o Note: Exceptions can be made for patients with prior invasive malignancy if determined by the PI/Co-PI, then the patient can proceed with protocol activities
• Prior systemic chemotherapy for the study cancer o Note: prior chemotherapy for a different cancer is allowable
• Severe, active co-morbidity defined as follows:
• Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
• Transmural myocardial infarction within the last 6 months
• Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
• Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 30 days of registration
• Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
• Lack of ability to understand and willingness to sign a written informed consent and complete questionnaires.

Related Conditions & MeSH terms

• Carcinoma
• HPV
• HPV Positive Oropharyngeal Squamous Cell Carcinoma
• HPV-Related Carcinoma
• HPV-Related Malignancy
• Oropharyngeal Neoplasms
• Oropharynx Cancer
• Papilloma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Diagnostic Test:
• HPV ctDNA Assay
HPV ctDNA evaluation will be completed using NavDx which is a validated digital droplet PCR (ddPCR) assay that targets primers and hydrolysis probes to specifically detect amplicons within the E6 and E7 genes encoded by high-risk HPV strain 16, and the E7 gene for high-risk HPV strains: 18, 31, 33, and 35.
• MRI Studies
Research MRI studies will be acquired at Memorial Sloan Kettering using a fast multi-phase spoiled gradient echo sequence. A Gadolinium-based agent will be used for DCE-MRI studies.

Behavioral:
• EORTC QLQ H&N 35 and C30
The EORTC QLQ H&N 35 s a validated 35-item site specific assessment tool. The module uses 7 multi-item scales to measure problems with swallowing, senses, speech, social eating and social contact. In addition, 11 single-item scales are utilized in assessing problems with teeth, mouth opening, dry mouth, sticky saliva, coughing, feeling ill, as well as use of analgesics, nutritional supplements, feeding tube and finally, weight gain and weight loss. All of the scales and single item measures range in score from 0 to 100. High scores for the Global Health Status/QoL scale represent high QoL, high scores for the functional scales represent high/healthy levels of functioning, but high scores for the symptom scales/items represent high levels of symptomatology/problems. Scoring the two instruments yields a total of 33 distinct scores and we will examine all of these scored.
• MDADI-HN
The MDADI-HN is a questionnaire scored on a scale of 1 to 5, consisting of global, emotional, functional, and physical subscales. The MDADI-HN evaluates the effects of dysphagia on QOL.
• COST-FACIT
Comprehensive Score for financial Toxicity or COST survey is a validated screening tool to assess objective and subjective questions about treatment-related financial distress. It is scored from 0-44, where lower composite scores reflect greater risk of financial toxicity.

Radiation:
• Intensity-Modulated Radiation Therapy (Arm A)
59.4-60 Gy in 1.8-2 Gy fractions: CTV_primary, Involved/Adjacent to nodal levels. 50 Gy to this volume is allowed as per MSK institutional standards in patients with clear or close margins and 2-4 involved nodes. 45-50.4 Gy in 1.8-2 Gy fractions: Dissected node positive neck: uninvolved levels that are not adjacent to positive node - Dissected node negative neck

Combination Product:
• Chemoradiation (Arm B)
30 Gy in 2 Gy fractions: CTV_primary, CTV_node-positive neck, CTV_node-negative neck, received de-escalated postoperative chemoradiation. Adjuvant radiation will be administered as previously outlined. Concurrent chemotherapy will be administered as per standard of care. Cisplatin will be administered concurrently with radiation. For non-cisplatin candidates, carboplatin/5fu will be administered. Reasons for using carboplatin/5FU instead of cisplatin need to be charted in the medical record, but the decision belongs to the treating physician. Cisplatin may be given up to 3 days before the scheduled dates, if necessary for medical or personal reasons

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Basking Ridge (Limited protocol activities)	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)	Commack	New York
United States	Memorial Sloan Kettering Westchester (Limited Protocol Activites)	Harrison	New York
United States	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	New Jersey
United States	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	New York
United States	Memorial Sloan Kettering Nassau (Limited protocol activities)	Rockville Centre	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathologically confirmed progression free survival	To estimate pathologically confirmed progression free survival (pPFS) two years post-operatively in HPV associated OPC patients who undergo active surveillance.	2 years

External Links

•   Memorial Sloan Kettering Cancer Center